Introduction: Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with EGFR-mutant lung cancers. However, the therapeutic efficacy of TKIs in patients with uncommon EGFR mutations remains unclear.
Introduction
EGFR mutations are reported in approximately 10% to 30% of NSCLCs worldwide. [1] [2] [3] These mutations occur in the tyrosine kinase domain and result in ligandindependent activation of the receptor and signaling through downstream prosurvival and antiapoptotic pathways. The most common EGFR mutations are in-frame deletions in exon 19 and the L858R point mutation in exon 21. 3 Most patients whose tumors harbor these classic mutations have significant radiographic and clinical responses to the first-generation reversible adenosine triphosphate-competitive EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib and the second-generation irreversible TKI afatinib. 1, 4, 5 However, less common mutations are found in approximately 10% to 15% of EGFR-mutant lung cancers, 3, 6 and the relevance of these mutations as clinical biomarkers for targeted therapy has not been clearly established. Here, we describe the identification of novel EGFR L858M/L861Q mutations in cis (on the same *Corresponding author.
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allele) in a patient with NSCLC that confer decreased sensitivity to first-and third-generation EGFR TKIs while retaining responsiveness to afatinib. Our findings suggest that afatinib may be a beneficial therapeutic option for patients with rare EGFR mutations with primary resistance to first-generation EGFR inhibitors.
Materials and Methods

Patient Information
The patient, a 62-year-old white female with less than a 1-pack-year smoking history, presented with symptoms of shortness of breath that were initially thought to be panic attacks. Two months later, her exertional shortness of breath worsened. A chest radiograph was obtained and identified a diffuse infiltrative process predominately in the upper lobes. A chest computed tomography scan identified irregular interlobular septal thickening predominately in the upper lobes along with nodularity in a subpleural distribution. Given the diffuse nature of the process, a video-assisted thoracoscopic surgical wedge resection from the right upper and middle lobes was performed. Pathologic evaluation demonstrated extensive involvement by a poorly differentiated adenocarcinoma. Immunohistochemistry demonstrated the tumor cells to be positive for cytokeratin 7, carcinoembryonic antigen, and thyroid transcription factor 1, with focal cells also staining positive for mucin. The patient's tumor specimen was sent for targeted next-generation sequencing (NGS) to help guide treatment.
DNA Extraction, NGS, and Data Analysis
Targeted sequencing was performed by using an NGS assay (OncoPanel, Dana-Farber Cancer Institute, Boston, Mass.) to detect single-nucleotide variants, small insertion-deletion mutations, copy number variations, and structural variants in tumor DNA extracted from fresh, frozen, or formalin-fixed paraffin-embedded samples containing at least 20% tumor cells. [7] [8] [9] The assay covers the complete exonic sequences of 300 cancer genes and 113 introns across 35 genes for genomic rearrangements.
Cell Lines and Reagents
Ba/F3 cells were maintained in Roswell Park Memorial Institute-1640 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco), and NIH-3T3 cells were maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. EGFR L858R Ba/F3 and EGFR L858R NIH-3T3 cells were generated as previously described. 10, 11 Gefitinib, afatinib, and osimertinib were purchased from Selleck Chemicals (Houston, TX), and stock solutions of drugs were prepared in DMSO.
EGFR L858M/L861Q-Mutant Construct and Retroviral Infection
The L858M and L861Q point mutations were introduced into human EGFR complementary DNA by sitedirected mutagenesis using the Quick Change Site-Directed Mutagenesis kit (Stratagene, San Diego, CA) according to the manufacturer's protocol with the following primers: 5 0 -TTCCGCACCCAGCTGTTTGGCCATCCCAAAATCTGTG-3 0 and 5 0 -CACAGATTTTGGGATGGCCAAACAGCTGGGTGCGGAA-3 0 . Successful generation of the construct was confirmed by DNA sequencing. The construct was shuttled into the retroviral vector JP1540 using the Agilent Cre Recombinase kit (Agilent Technologies, Santa Clara, CA). Ba/F3 and NIH-3T3 cells were infected with retrovirus according to standard protocols. 12 Stably transfected cell lines were obtained by puromycin selection (2 mg/mL) (SigmaAldrich, St. Louis, MO) for NIH-3T3 cells and by puromycin selection and interleukin-3 withdrawal for Ba/F3 cells. EGFR expression was verified by Western blotting, and pooled stable cells were used for the experiments.
Cell Proliferation Assays
Cell growth and growth inhibition were assessed by MTS assay. A total of 3000 cells were seeded per well in 96-well plates and exposed to drug (3.3 nM to 10 mM) for 72 hours. All experimental points included six to 12 wells, and data were averaged from three independent experiments. Data were displayed graphically by using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA), and the curves were fitted by using a nonlinear regression model with sigmoidal dose response.
Western Blotting Analysis
EGFR L858R and EGFR L858M/L861Q NIH-3T3 cells were plated at 1 Â 10 6 cells per 10-cm plate and treated with the indicated concentrations of inhibitors for 6 hours the next day. After 6 hours of treatment, cells were washed with phosphate-buffered saline and lysed with NP40 buffer (Calbiochem, San Diego, CA) supplemented with Complete Mini protease inhibitor and PhosSTOP phosphatase inhibitors (Roche Molecular Systems, Pleasanton, CA). Lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, transferred to nitrocellulose membranes, and probed with the following antibodies: phospho-EGFR(Y1068) (3777), total EGFR (2232) (Cell Signaling Technology, Danvers, MA), and tubulin (T9026) (Sigma Aldrich). Densitometry was performed with ImageJ software (National Institutes of Health, Bethesda, MD). Samples were normalized to tubulin before determining the ratio of phospho-EGFR in treated versus untreated samples.
Results
Targeted NGS of the patient's tumor revealed two EGFR mutations, L858M (in 30% of 190 reads) and L861Q (in 28% of 175 reads). These two mutations were in cis with one another (Fig. 1) . On the basis of these findings, the patient began receiving erlotinib therapy, 150 mg once daily, 4 months after initial presentation (Fig. 2) . At the time of erlotinib initiation, the patient was using supplemental oxygen (2-3 L/min). After 1 month of treatment, her erlotinib dose had to be reduced to 100 mg once daily because of skin toxicity. Repeat staging 2 months after initiation of erlotinib demonstrated stable disease (Fig. 2) . However, after 4 months of erlotinib therapy, the patient's shortness of breath and oxygen requirement (3-4 L/min) had worsened. She began combination chemotherapy with carboplatin and pemetrexed and received four cycles of treatment. Repeat imaging demonstrated a minor response. The patient still required supplemental oxygen (3 L/min) and had substantial shortness of breath. After 4 months of chemotherapy and the development of worsening shortness of breath, she was switched to afatinib, 40 mg once daily. The patient noted improvement in her breathing within just a few days of treatment. After 2 weeks of afatinib therapy, she no longer required supplemental oxygen and her shortness of breath had markedly improved. Repeated imaging after 2 months of afatinib therapy demonstrated a dramatic radiographic response (Fig. 2) . She has continued to receive afatinib for 10 months, with grade 1 diarrhea as her only side effect and is still undergoing treatment as of the writing of this report.
To understand whether the patient's resistance to erlotinib and sensitivity to afatinib could be explained by the unique EGFR L858M/L861Q mutations, the effect of the L858M/L861Q mutations on drug sensitivity was examined in vitro. Stable EGFR L858M/ L861Q Ba/F3 cells were generated, and cell viability/ proliferation after treatment with EGFR TKIs was measured by MTS assay. Compared with EGFR L858R-mutant cells, L858M/L861Q cells demonstrated reduced sensitivity to gefitinib treatment (28.3 nM for L858R IC50 versus 169.1 nM for L858M/L861Q IC50) ( Fig. 3A and B) , but the response to afatinib was similar for both cell lines (1.5 nM for L858R IC50 versus 1.8 nM for L858M/L861Q IC50). In addition, L858M/ L861Q cells exhibited decreased sensitivity to osimertinib, a third-generation irreversible and mutantspecific EGFR inhibitor (8.0 nM for L858R IC50 versus 28.8 nM for L858M/L861Q IC50) (Fig. 3A and  B) . Using stable EGFR L858M/L861Q NIH-3T3 cells, we examined the capacity of gefitinib, afatinib, and osimertinib to prevent EGFR phosphorylation by Western blotting. Gefitinib and osimertinib inhibited EGFR L858M/L861Q phosphorylation less potently than EGFR L858R (Fig. 3C) , whereas afatinib treatment significantly reduced EGFR L858M/L861Q phosphorylation even at low concentrations.
Discussion
In the era of precision medicine, genotyping of EGFR has become a standard practice for NSCLC, but the identification of a rare mutation does not necessarily indicate a clear course of action for therapy. This is the first report of a patient with EGFR-mutant lung cancer with primary resistance to erlotinib but responsiveness to afatinib, and our in vitro findings indicate that this therapeutic response was the result of rare EGFR L858M/L861Q cis mutations in the patient's tumor. According to the Catalogue of Somatic Mutations in Cancer database (version 78), EGFR L858M/L861Q cis mutations have been reported in three other patients with lung cancer, although no data are available on the treatment or outcome of these patients. [13] [14] [15] Previous reports suggest that patients with EGFR L861Q mutations have a response rate of 50% to 60% to gefitinib and erlotinib, responding less favorably than patients with the more common L858R point mutation or exon 19 deletion. 6, 16 Similarly, our May 2017 EGFR L858M/L861Q Confers Afatinib Sensitivityfindings suggest that the potency of first-generation inhibitors to prevent EGFR signaling is reduced in the setting of the L858M/L861Q mutation. Additionally, our results indicate that treatment with the mutant-specific inhibitor osimertinib may not sufficiently inhibit EGFR L858M/L861Q signaling, suggesting that afatinib may be the most beneficial first-line therapy for a subset of patients with rare EGFR mutations. Together, these data suggest that the various EGFR inhibitors may have distinct capabilities to inhibit signaling of specific EGFR mutants. Additional studies to understand how uncommon mutations affect EGFR protein structure and TKI binding, as well as studies to measure the potency of TKIs in the setting of rare mutations, will provide valuable therapeutic insight for NSCLC patients with uncommon EGFR mutations in their tumors.
